322 related articles for article (PubMed ID: 18288280)
1. PPAR Agonists and Cardiovascular Disease in Diabetes.
Calkin AC; Thomas MC
PPAR Res; 2008; 2008():245410. PubMed ID: 18288280
[TBL] [Abstract][Full Text] [Related]
2. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
3. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
4. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists.
Gervois P; Fruchart JC; Staels B
Int J Clin Pract Suppl; 2004 Oct; (143):22-9. PubMed ID: 16035393
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
Wagner N; Wagner KD
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768666
[TBL] [Abstract][Full Text] [Related]
6. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
7. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
[TBL] [Abstract][Full Text] [Related]
8. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
9. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
Chigurupati S; Dhanaraj SA; Balakumar P
Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
12. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
13. Regulation of peroxisome proliferator-activated receptors (PPAR) α and -γ of rat brain astrocytes in the course of activation by toll-like receptor agonists.
Chistyakov DV; Aleshin SE; Astakhova AA; Sergeeva MG; Reiser G
J Neurochem; 2015 Jul; 134(1):113-24. PubMed ID: 25818681
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
Liu J; Wang LN
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD010693. PubMed ID: 29197071
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors in diabetic nephropathy.
Kume S; Uzu T; Isshiki K; Koya D
PPAR Res; 2008; 2008():879523. PubMed ID: 19277201
[TBL] [Abstract][Full Text] [Related]
17. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
18. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
19. [Development of a cell-based peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of triterpenoids isolate from Alismatis Rhizoma].
Li XY; Wang XH; Huang XQ; Wu TT; Xu W; Wu SS
Zhongguo Zhong Yao Za Zhi; 2016 Nov; 41(21):4015-4022. PubMed ID: 28929690
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Staels B; Fruchart JC
Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
